CD8A and lung carcinoma: As both responders and non‐responders contained comparable proportions of lung cancer‐specific CD4 and CD8 T cells in our cohort of patients before the start of therapy, the experimental evidence pointed to the baseline intrinsic functionality of CD4 immunity as the key factor in our study.